Summary: To investigate the hypothesis that survivors of pediatric solid cancer have low bone mineral density, a cross-sectional study was done of subjects who had received treatment for pediatric solid tumors before 16 years of age and were less than 40 years old at follow-up. Excluded were subjects treated for acute lymphoblastic leukemia or those who had received cranial irradiation, total body radiation, or nonautologous bone marrow transplant. The study group consisted of 38 subjects, with the most common diagnoses being lymphoma (n = 17), sarcoma (n = 8), Wilms tumor (n = 5), and neuroblastoma (n = 4). Median age was 22 years (range 12-32). Time from diagnosis of underlying cancer averaged 12.6 years (range 5.5-20.3). Using criteria of osteopenia (Z-score #21.0 and .22.0) and osteoporosis (Z-score # 22.0) for any one or more areas including total body, lumbar spine, total hip, or femoral neck density, 13 of the 38 subjects (34%) had osteopenia or osteoporosis. A further six subjects (16%) had isolated upper extremity osteopenia or osteoporosis. Multivariate analysis showed a direct relationship between the number of chemotherapy drugs administered and the presence of osteopenia or osteoporosis in the lower extremities (P = 0.03). Young survivors of childhood solid tumors are at increased risk of developing premature osteopenia or osteoporosis, and screening evaluations and follow-up are warranted.
S
urvivors of childhood cancer are now reaching adulthood in increasing numbers. The late effects of these malignancies and their treatments on the health status of adult survivors have begun to receive more attention. 1 Currently one in every 900 individuals between the ages of 15 and 45 years is a childhood cancer survivor. 2 This growing population represents a new group at risk for, among other problems, osteoporosis. Specific subgroups of children who survive treatment of childhood malignancies have been shown to develop osteopenia following treatment and are thought to be at risk for developing osteoporosis and fractures later in life due to their inability to reach peak bone mass during childhood. 3, 4 In particular, childhood survivors of acute lymphoblastic leukemia (ALL) and brain tumors have been clearly shown to be in the high-risk group for developing osteoporosis. However, little is known regarding the risk of developing osteoporosis among survivors of childhood solid tumors. 5 Osteopenia has been reported in small series of pediatric solid malignant tumor survivors in the literature, but conclusive evidence identifying these subjects as high risk has not been established. 5, 6 This problem is only beginning to be addressed in the literature. 6 Prospective studies have shown that determinations of bone mineral density (BMD) can predict future fractures and identify subjects at greatest risk for osteoporosis. 1 Our primary hypothesis for this cross-sectional densitometry study is that survivors of pediatric solid cancer have significantly lower BMD compared with established agematched controls.
METHODS
Subjects from the SUNY Upstate Medical University Pediatric Oncology long-term survivor KNOT (Kids Now Off Therapy) clinics who were treated for solid tumors and lymphomas with cancer therapy beginning at age less than 16 were recruited for participation. Subjects had to be less than 40 years of age at the time of the study to participate. Subjects were excluded if they were treated for ALL or if they had received cranial irradiation, total body irradiation, or a nonautologous bone marrow transplant, as these treatments are known risk factors for osteoporosis. Institutional Review Board approval was obtained for this project, and all subjects gave informed consent. Oncologic data obtained from their medical records included tumor type and grade, location of tumor, duration and type of chemotherapeutic agents received, cancer-related surgeries, and radiotherapy treatment, dose, duration, and location.
All participants completed a questionnaire that included general demographic information as well as questions about personal and family history of fracture, lifestyle behaviors, calcium intake, activity level, medication use, and family history of significant diseases. They were specifically asked about any history of steroid, anticonvulsant, antimetabolite, or thyroid and sex hormone use. Women were asked about their menstrual history.
Subjects
A total of 38 subjects were eligible for inclusion during the period of data collection and were enrolled in our study. They represented the following diagnoses: lymphoma (n = 17), sarcoma (n = 8), Wilms tumor (n = 5), neuroblastoma (n = 4), ovarian germ cell tumor (n = 1), yolk sac carcinoma (n = 1), Triton tumor (n = 1), and hepatoblastoma (n = 1). One subject was French/Indian, but all others were Caucasian. There were 21 males and 17 females with a median age of 22 6 5 years (range 12-32) at latest follow-up. Fifteen subjects were considered pediatric (,20 years) at follow-up. Mean height was 168.8 cm (range 153.4-188.2), mean weight was 68.9 kg (range 43.3-127.6), and mean body mass index (BMI) was 24.0 kg/m 2 (range 17.7-42.2). Mean age at diagnosis was 8.9 6 5.4 years (range 0-17.7). These diagnoses were made between November 1981 and January 1997. Follow-up from the diagnosis of cancer averaged 12.6 6 3.6 years (range 5.5-20.3). Thirty-six of the 38 subjects received chemotherapy for an average duration of 38.5 6 17 weeks. Twelve subjects had received methotrexate and eight had received prednisone (Table 1) . Eighteen subjects received radiotherapy to one or more fields, and seven of those received additional courses of irradiation to more than one field later in their treatment. Total radiation dose ranged from 1,050 cGy for Wilms tumor to 4,494 cGy for hepatoblastoma. The most common radiotherapy field was mantle radiation (six patients), but the total dose ranged from 2,100 to 4,025 cGy. Two subjects with nodular sclerosing Hodgkin's disease received only radiotherapy at the exclusion of chemotherapy.
The tumor stages (staged by conventional criteria) of the most common types of tumors diagnosed in our study group were as follows. Of the subjects with lymphoma, two subjects were stage I, six were stage II, eight were stage III, and one was stage IV. Of the subjects with Wilms tumor, based on the National Wilms Tumor Study Group clinicopathologic staging system, one subject was stage I, two were stage II, one was stage III, and one was stage V (bilateral). Of the subjects with neuroblastoma, two were stage 3 and two were stage 4S according to the International Neuroblastoma Staging System. Of the subjects with sarcoma, all six bone sarcomas (five osteosarcomas and one Ewing sarcoma) were Musculoskeletal Tumor Society (MSTS) stage IIA or IIB; both rhabdomyosarcomas were in clinical group 3 (one each IIIA and IIIB according to the Intergroup Rhabdomyosarcoma Study Group); and the Triton tumor was MSTS stage IIB.
Osteoporosis questionnaires showed that only two subjects were aware of having previously had BMD assessment that showed osteopenia or osteoporosis, both after completing diagnosis and treatment. Seven subjects had a family history of osteoporosis in a family member. One subject each had diabetes, mild renal insufficiency, and chronic diarrhea. Seven subjects had hypothyroidism. No subject had liver disease, other known bone diseases, or rheumatoid arthritis. Menarche had begun at ages ranging from 11 to 14 years, but two subjects were amenorrheic, one having never achieved menarche.
Thirty-one subjects consumed milk or other calciumrich foods, but only eight subjects were taking calcium supplements. Exercise level in the preceding 6 months leading up to completion of the questionnaire was self-rated as low in 12, low to moderate in 1, moderate in 16, moderate to high in 1, high in 4, and very high in 4. Exercise during the subjects' youth was self-rated as low in 5, moderate in 6, moderate to high in 4, high in 13, high to very high in 4, and very high in 6. No definitions were supplied to the patients for this purely subjective, self-administered exercise rating system, and no validation of this item in the questionnaire has been done to date.
Densitometry Technique
After enrollment, the participants each had BMD measurements obtained at the following sites: total body, lumbar spine (L2-4), and bilateral upper and lower extremities including distal forearm (ultra-distal [UD radius] and 33% radius) and proximal femur (total hip and femoral neck). The measurements were made on a GE-Lunar DPX-IQ dual energy x-ray absorptiometer (DEXA) located at the Institute for Human Performance. All measurements were made by the same operator, with daily quality assurance checks against a density calibration phantom.
The reference population for the adult subjects (age $20 years) was that of the GE-Lunar data base for all sites measured. These age-and gender-specific reference data were generated by the manufacturer for U.S. populations on the same type of instrument used in this study. For the pediatric subjects (ages 5-19 years), GE-Lunar age-and gender-specific reference data were used for the total body and spine sites. For the femoral neck Z-scores, a published reference database from 514 females and 330 males using a Lunar DPX machine was used. 7 Subjects without Z-scores for a specific site were excluded from the analysis for that site. 
Definition of Low BMD
The subjects were classified according to their respective Z-score. A Z-score of less than or equal to 21.0 but greater than 22.0 was classified as ''osteopenia'' and a Z-score of less than or equal to 22.0 was classified as ''osteoporosis'' for all sites measured. This simplification of the WHO classification is recommended by the International Society for Clinical Densitometry (ISCD). 8 
Metabolic Markers
Two widely used serum markers of bone metabolism were analyzed for the subjects: bone-specific alkaline phosphatase (BAP) and N-telopeptides (NTx). The serum was collected at the time of DEXA analysis for each subject. The Osteomark NTx serum kit (Ostex International, Seattle, WA), a competitive inhibition enzyme-linked immunosorbent assay (ELISA) that allows quantitative determination of cross-linked N-telopeptides of type 1 collagen (NTx) from human serum, was used to evaluate bone resorption. BAP was measured using the Metra BAP kit (Quidel Corp, San Diego, CA) as a measure of osteoblast activity and thus bone formation. Assays of serum samples, appropriate reference samples, and range controls were performed as per the manufacturer's recommendations. Optical densities for each sample duplicate were averaged, and assay values were extrapolated from the standard fit curves, expressed as nanomolar bone collagen equivalents (NTx) or units/liter serum (BAP).
Statistical Analysis
All analysis was performed using SAS-PC for Windows, version 8.02, by our statistician (W.G.). Initial data reduction was completed using means and frequencies as appropriate. Any potential relationships between categorical variables were assessed using chi-square analysis. Relationships between continuous variables were examined using ANOVA. Exploratory multivariate analysis was conducted using SAS PROC DISCRIM examining various combinations of proposed demographic and treatment variables thought to have a possible effect on BMD. A comprehensive analysis was not possible due to the small sample size. These included age, gender, body type, age at diagnosis, disease diagnosis, tumor grade, specific chemotherapy drugs individually, chemotherapy divided into drug classes, radiotherapy, variables from the osteoporosis questionnaire, and duration of time since diagnosis. A logistic regression analysis was performed for both BAP and NTx levels relative to the presence or absence of any site of osteopenia in the subjects. Specific quantification of NTx values greater than 40 nM was not feasible with the kit used for analysis, so for statistical purposes these were considered equal to 40 nM.
For each location scanned by DEXA, the following regions were analyzed separately: AP lumbar spine, left total hip, left femoral neck, right total hip, right femoral neck, left UD radius, left 33% radius, right UD radius, and right 33% radius. Subsequent analysis also examined grouped locations including upper extremities (UD and 33% radius combined), lower extremities (total hip and femoral neck combined), and spine. For the upper and lower extremity groups, osteopenia or osteoporosis at either site was interpreted as the presence of osteopenia or osteoporosis, respectively, for the region as a whole. Chemotherapy agents were identified by class for evaluation (see Table 1 ).
RESULTS
Overall, half of our subjects had osteopenia or osteoporosis in at least one site examined. For any one or more sites of total body, spine, total hip, or femoral neck, 13 of the 38 (34%) subjects had decreased BMD (9 subjects [24%] with osteopenia, 4 subjects [10%] with osteoporosis) (Fig. 1) . In addition, a further six (16%) subjects had evidence of isolated upper extremity osteopenia (n = 3) or osteoporosis (n = 3). One subject had total body osteopenia and none had total body osteoporosis. Only three subjects had Z-scores less than 22.5, all occurring in the total hip or femoral neck region.
Of the 19 subjects with osteopenia or osteoporosis of any site, 10 had decreased BMD in the spine or multiple sites, 6 had only upper extremity osteopenia or osteoporosis, and 3 had isolated unilateral lower extremity osteopenia or osteoporosis (2 with ipsilateral osteosarcoma of the femur) ( Table 2 ). In 5 of the 11 subjects with upper extremity involvement (including 2 of 6 subjects with isolated upper extremity involvement), both extremities were affected. In three of the other six subjects, unilateral upper extremity involvement accompanied other sites with decreased BMD. Both subjects who had been found to have osteopenia on earlier studies still had osteopenia on the current evaluation.
Five of the six subjects with extremity bone sarcomas had at least regional osteopenia or osteoporosis in the involved extremity. Two of these five had osteopenia or osteoporosis only in the involved extremity; both of the subjects had femoral osteosarcomas. The other three subjects with regional osteopenia or osteoporosis also had other sites involved. None of the subjects with soft tissue sarcomas (two rhabdomyosarcoma, one Triton tumor) showed any site of low BMD. FIGURE 1. Prevalence of low bone mineral density (BMD) (defined as a Z-score of less than 21) in the 38 study subjects is shown according to whether the osteopenia or osteoporosis occurred isolated to the upper extremities or to one or more other sites. Total body (TB), lumbar spine (S), total hip (H), femoral neck (FN), and upper extremity (UE) sites are included. The absolute numbers and percentage of the total subject population are shown.
Among the 18 subjects who had received irradiation, there were 9 with Hodgkin's disease, 3 with Wilms tumor, 2 with rhabdomyosarcoma, and 1 each with Ewing's sarcoma, mixed germ cell tumor of the ovary, neuroblastoma, and hepatoblastoma. Low BMD was evident in four of the nine Hodgkin's disease subjects, all of whom had received mantle irradiation. In fact, four of the six subjects who had received mantle irradiation for Hodgkin's disease developed osteopenia, three including at least upper extremity sites.
Nine of the 38 subjects had a history of one or more fractures that occurred after treatment (Table 3) . Five of the nine subjects with fracture had a low BMD in the area of their fracture. Another three of the nine subjects did not have any areas of low BMD, and the remaining subject had low BMD found in areas outside of where the fracture occurred. The number of subjects in the fracture group was too small to allow meaningful statistical analysis.
Based on a multivariate analysis, the only significant relationship found was a direct relationship between the number of drugs administered and the presence of osteopenia or osteoporosis in the lower extremities (Fig. 2) . No single treatment agent (chemotherapeutic drug, steroid, or radiotherapy) could be isolated as a potential causative factor. No significant relationship was noted between duration of chemotherapy and osteopenia or osteoporosis. There was no significant relationship between osteopenia or osteoporosis and the presence of any of the following factors: endocrinopathies, gastrointestinal disturbances, smoking, hormonal replacement, caffeine consumption, supplemental calcium intake, use of milk products, Northern European descent, thin body habitus, or amenorrhea or dysmenorrhea.
The subjects with osteopenia or osteoporosis had significantly lower BAP and NTx levels compared with those with normal BMD (Table 4 ). The decrease in BAP in the osteopenia or osteoporosis subjects was of greater magnitude [7] ,0.0001
Note: Mean Z-scores are shown separated by those subjects with and without presence of osteopenia, defined as Z score less than or equal to negative 1.0, according to body area examined during DXA study. All differences between those with and without osteopenia at each site were statistically significant (p , 0.05). Standard deviations are shown in parentheses followed by number of subjects in brackets. 
Note: BMD, bone mineral density; L, left; R, right; FN, femoral neck region; UD, ultra-distal radius. than the decrease in NTx. However, the paired ratios of each subject's BAP to NTx were not significantly less for the subjects with osteopenia or osteoporosis compared with those with normal BMD. Logistic regression analysis of the BAP levels relative to whether the subjects had any evidence of osteopenia or osteoporosis at any site suggested significant relationships between osteopenia or osteoporosis and both decreased BAP (Wald chi-square estimate 0.05 U/L, P = 0.03; intercept estimate 22.02, P = 0.03) and decreased NTx levels (Wald chi-square estimate 0.13 nM, P = 0.02; intercept estimate 22.10, P = 0.02).
DISCUSSION
Our data confirm our hypothesis that adult survivors of pediatric solid tumors are at an increased risk of developing at least regional osteopenia or osteoporosis prematurely. While other studies of survivors of childhood cancer have included higher numbers of solid tumor survivors, to our knowledge this current study is the first report limited to survivors of pediatric solid tumors that has examined BMD in a crosssectional fashion. In these subjects the BMD was significantly lower when compared with a young, healthy, age-matched reference population. Fifty percent of the 38 subjects in this study showed at least regional osteopenia or osteoporosis. Most of the subjects found to have low BMD had multiple sites involved. The only statistically associated variable was the number of chemotherapeutic drugs administered. As a correlate to these findings, the subjects with osteopenia or osteoporosis had significantly decreased osteoblastic activity, as evidenced by decreased BAP levels. Furthermore, the resulting ratio of bone formation to bone resorption favored resorption more in those subjects with osteopenia or osteoporosis compared with subjects with normal BMD.
Foremost among groups of childhood cancer survivors previously identified to be at increased risk for osteopenia and osteoporosis are survivors of ALL, as well as subjects who received cranial irradiation. 3, 4, 5, 9 Identification of other risk factors and high-risk groups will be important to establish targets for similar treatment and prophylactic interventions to prevent osteoporosis in those subjects' futures. However, in the current study, none of the variables found to be important in those groups (age, specific drugs, exercise capacity, physical activity) showed a significant relationship to the presence of osteopenia or osteoporosis.
The prevalence of low BMD in this population of solid tumor survivors differs from that previously reported. Recently, Holzer et al 6 assessed BMD in 48 long-term survivors of osteosarcoma. Using WHO guidelines, 10 of the 48 subjects (20.8%) were found to be osteoporotic and 21 of the 48 (43.7%) to be osteopenic. The higher percentage of subjects in their study found to have low BMD (64.5% vs. 50%) may be explained by the greater mean age of the subjects (31 years vs. 22 years) and longer mean time to follow-up (16 years vs. 12.6 years) compared with our study. In contrast to Holzer et al's report, Henderson et al 10 in an earlier study assessed BMD in 60 survivors of childhood malignancies; 15 had solid tumors and the other 45 had predominately acute lymphocytic leukemia. Henderson et al reported that BMD using Z-scores was normal in most solid tumor survivors, but the age of their subjects (mean 12.4 years) was much younger than either the current series or that of Holzer et al, and the duration off chemotherapy was also short (mean 4.3 years). It may be that the longer the time from treatment of the childhood malignancy, the more likely low BMD will be manifest.
The etiology of the decreased BMD in this population of solid tumor survivors is probably multifactorial. Skeletal manifestations in children and adolescents who have been treated for a malignancy are not unexpected, as exposure to multiple agents is thought to impair the acquisition of bone mass. Aisenburg et al reported on DEXA analysis of 40 subjects from their long-term survivor clinic at Cornell, including 16 solid tumors and 14 lymphomas. 1 The overall group's BMD was significantly reduced compared with controls at the distal radius/ulna, femoral neck, and total body. However, only gonadal dysfunction, not underlying disease, showed a significant relationship with reduction in BMD, and cytotoxic chemotherapy was implicated as the primary etiologic agent. Prolonged bed rest and poor nutrition with the inherent alterations in vitamin D metabolism, growth hormone deficiency, and changes in insulin-like growth factors might also be contributing factors, although none of those that were able to be analyzed in the current study were statistically implicated.
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The greater the number of drugs received during treatment in the current series, the significantly higher the incidence of osteopenia or osteoporosis. No prior reports described this association. However, some reports have implicated chemotherapeutic drugs as the most likely cause of low BMD in this population. 12 Arikoski et al, based on their analysis of 46 children with newly diagnosed cancer treated with chemotherapy, concluded that treatment components, rather than disease type, contributed to the observed decrease in BMD. 12 Although no specific antineoplastic agents were implicated in their study, cumulative chemotherapy doses did show a relationship. It stands to reason that corticosteroids and other antineoplastic agents that interfere directly with the development of bone mass would have an additive detrimental effect on bone density. 11 The results of the current study are the first to statistically support the cumulative effect of chemotherapeutic agents on developing bone density. One of the most important clinical concerns in subjects with low BMD is the risk for fractures. Although 9 of our 38 subjects had a history of fracture, the small numbers did not allow a demonstration of a direct association with osteopenia or osteoporosis. The association of low BMD and fracture is usually strongest for sites generally considered at risk in osteoporosis (wrist, forearm, rib, spine, and hip), but it can be apparent for fractures at other sites as well. 13 Eight of our subjects had low BMD isolated to the upper or lower extremity. Three of those had decreased BMD isolated to the extremity involved by a sarcoma that had undergone surgical resection or irradiation. A fourth subject with lower extremity sarcoma had ipsilateral osteopenia in addition to spinal osteopenia. In this subset of the overall solid tumor survivor population, regional osteopenia is likely attributable to the damaging effects of local irradiation, disuse effects from prolonged immobilization, or limited weight-bearing following some surgical reconstructions. Both of the subjects with isolated lower extremity osteopenia/osteoporosis had been treated for ipsilateral femoral osteosarcomas. On the other hand, peripheral BMD measurement can be predictive of fracture risk at both peripheral and central sites. 13, 14 Only further study with larger numbers of subjects and longer follow-up will clarify the significance of these regional BMD decreases.
Specific limitations of this study must be considered in interpretation of the results. First, the small number of subjects studied limits the power to show statistical differences between groups, which is a common limiting factor in other studies published in this area. A meta-analysis of combined study data would address this issue. Second, some questions on the osteoporosis questionnaires did not provide meaningful detail, including those for calcium intake and the mechanism of injury resulting in previous fractures. Third, the database used to calculate Z-scores for our pediatric subjects, although the best available for the GE-Lunar DPX-IQ densitometer at the current time, is more limited than that used for the adults. Because there were no data available for Z-scores to be calculated at sites other than total body, femoral neck, and spine in our pediatric subjects, our analysis remains incomplete. Further expansion of normative databases to pediatric populations would be helpful to allow more extensive analysis of this data in the future. 2 Finally, DEXA planar densitometry may not adequately reveal changes in bone quality and structure that could also be present in these subjects.
To our knowledge, this is the first study to exclusively evaluate adult survivors of childhood solid tumors for osteopenia or osteoporosis. The prevalence is approximately one half of subjects, and many will have only regional involvement. This subject population should continue to undergo BMD screening starting in young adult life.
